游客发表

【do post nuptial agreements hold up in court】Aptose to Hold Corporate Update Sunday, December 6th

发帖时间:2024-10-04 05:05:51

Corporate event to provide

clinical

【do post nuptial agreements hold up in court】Aptose to Hold Corporate Update Sunday, December 6th


update for

【do post nuptial agreements hold up in court】Aptose to Hold Corporate Update Sunday, December 6th


CG-806

【do post nuptial agreements hold up in court】Aptose to Hold Corporate Update Sunday, December 6th


in AML and B-cell Cancers


Poster Presentations for CG-806 and APTO-253 are scheduled for December


5


th


and


6


th


at 2020 ASH Annual Meeting and Exposition


SAN DIEGO and TORONTO,do post nuptial agreements hold up in court Dec. 01, 2020 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose”) (NASDAQ: APTO, TSX: APS), a clinical-stage company developing highly differentiated therapeutics targeting the underlying mechanisms of cancer, today announced that the company management team will provide a corporate update on Sunday, December 6


th


, at 2:00 PM PT, in conjunction with participation at the 2020 ASH Annual Meeting. The event will include the current clinical status of CG-806, Aptose’s oral, first-in-class FLT3 and BTK cluster selective kinase inhibitor currently in two Phase 1 a/b trials, one in patients with relapsed or refractory acute myeloid leukemia (AML) and another in patients with relapsed or refractory B cell malignancies, as well as a review of APTO-253, a first-in-class small molecule MYC inhibitor in a Phase 1 a/b trial in patients with relapsed or refractory AML or high risk myelodysplastic syndrome (MDS).


Aptose Corporate Update Details


Date


&


Time:


Sunday, December 6, 2020, 2:00 PM PT


Participant Webcast Link


:


http://public.viavid.com/index.php?id=142523


Participant Dial-in:


Toll Free:


Toll/International


:


Conference ID:


1-877-407-9039


1-201-689-8470


13713479


The slides will be available on Aptose’s website


here


and a recording of the presentation will be archived shortly after the conclusion of the event.


As announced previously, early clinical data, along with certain preclinical data for CG-806 and APTO-253, will be presented at the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, being held virtually Saturday, December 5 – Monday, December 7, 2020. The posters will be available on the presentations page of Aptose website


here


.


Poster Presentation Details


Abstract #1042:


A Phase 1a/b Dose Escalation Study of the MYC Repressor Apto-253 in Patients with Relapsed or Refractory AML or High-Risk MDS


Poster Session D


ate & Time:


Saturday, December 5, 2020, 7:00 AM - 3:30 PM PT


Session Name:


616. Acute Myeloid Leukemia: Novel Therapy, excluding Transplantation: Poster I


Abstract #1174


:


Pharmacologic Inhibition of B Cell-Receptor-Associated Kinases with CG-806 Induces Apoptosis and Metabolic Reprogramming in Aggressive Non-Hodgkin Lymphoma (NHL) Models


Poster Session


Date & Time:


Saturday, December 5, 2020, 7:00 AM - 3:30 PM PT


Session Name:


625. Lymphoma: Pre-Clinical—Chemotherapy and Biologic Agents: Poster I


Abstract #2228


:


A Phase 1 a/b Dose Escalation Study of the Mutation Agnostic BTK/FLT3 Inhibitor CG-806 in Patients with Relapsed or Refractory CLL/SLL or Non-Hodgkin’s Lymphomas


Poster Session


Date & Time:


Sunday, December 6, 2020, 7:00 AM - 3:30 PM PT


Session Name:


642. CLL: Therapy, excluding Transplantation: Poster II


About Aptose


Aptose Biosciences is a clinical-stage biotechnology company committed to developing personalized therapies addressing unmet medical needs in oncology, with an initial focus on hematology. The Company's small molecule cancer therapeutics pipeline includes products designed to provide single agent efficacy and to enhance the efficacy of other anti-cancer therapies and regimens without overlapping toxicities. The Company has two clinical-stage investigational products for hematologic malignancies: CG-806, an oral, first-in-class mutation-agnostic FLT3/BTK kinase inhibitor, is in a Phase 1 trial in patients with relapsed or refractory B cell malignancies, including chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL) and non-Hodgkin lymphoma (NHL), who have failed or are intolerant to standard therapies, and is in a separate Phase 1 trial in patients with relapsed or refractory acute myeloid leukemia (AML); APTO-253, the only known clinical stage agent that directly targets the MYC oncogene and suppresses its expression, is in a Phase 1b clinical trial for the treatment of patients with relapsed or refractory AML or high risk myelodysplastic syndrome (MDS).


For further information, please contact:


Aptose Biosciences Inc.


Greg Chow


Executive Vice President, CFO


858-926-2730


[email protected]


SMP Communications


Susan Pietropaolo


201-923-2049


[email protected]


LifeSci Advisors, LLC


Dan Ferry, Managing Director


617-430-7576


[email protected]


View comments


    热门排行

    友情链接